Advertisement

World Journal of Surgery

, Volume 35, Issue 8, pp 1879–1886 | Cite as

Review of the Pathogenesis, Diagnosis, and Management of Type I Gastric Carcinoid Tumor

  • Linda Zhang
  • Junko Ozao
  • Richard Warner
  • Celia Divino
Article

Abstract

Gastric carcinoid tumors comprise 7% of all gastrointestinal carcinoids and have significantly increased in incidence over the past few decades. Seventy to 80% of gastric carcinoids are type I, which usually are clinically asymptomatic and found incidentally at endoscopic evaluation for abdominal pain or anemia. In this review, advances in understanding the pathophysiology of type I gastric carcinoid are highlighted. In addition, various current diagnostic and treatment options are discussed. Although type I carcinoids generally hold a benign course, rigorous investigation is needed to ensure accurate diagnosis and optimal treatment. This includes appropriate diagnostic procedures and imaging and accurate staging of tumor. Tumor size, depth of invasion, presence of metastasis, and the tumor’s gastrin dependency dictate treatment options. Appropriate treatments can consist of endoscopic resection, antrectomy, medical management, or frequent follow-up. This article provides a systematic method of evaluating and treating type I gastric carcinoid.

Keywords

Carcinoid Tumor Endoscopic Mucosal Resection Chronic Atrophic Gastritis Gastric Carcinoid Open Distal Gastrectomy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Modlin IM, Lye KD, Kidd M (2004) A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 99:23–32PubMedCrossRefGoogle Scholar
  2. 2.
    Gencosmanoglu R, Sen-Oran E, Kurtkaya-Yapicier O et al (2003) Gastric polypoid lesions: analysis of 150 endoscopic polypectomy specimens from 91 patients. World J Gastroenterol 9:2236–2239PubMedGoogle Scholar
  3. 3.
    Dakin GF, Warner RR, Pomp A et al (2006) Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 93(5):368–372PubMedCrossRefGoogle Scholar
  4. 4.
    Borch K, Ahrén B, Ahlman H et al (2005) Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242(1):64–73PubMedCrossRefGoogle Scholar
  5. 5.
    Hosokawa O, Kaizaki Y, Hattori M et al (2005) Long-term follow-up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer 8:42–46PubMedCrossRefGoogle Scholar
  6. 6.
    Gough DB, Thompson GB, Crotty TB et al (1994) Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 18(4):473–479 discussion 479-480PubMedCrossRefGoogle Scholar
  7. 7.
    Annibale B, Azzoni C, Corleto VD et al (2001) Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol 13:1449–1456PubMedCrossRefGoogle Scholar
  8. 8.
    Modlin IM, Lye KD, Kidd M (2003) Carcinoid tumors of the stomach. Surg Oncol 12:153–172PubMedCrossRefGoogle Scholar
  9. 9.
    D’Adda T, Keller G, Bordi C et al (1999) Loss of heterozygosity in 11q13–14 regions in gastric neuroendocrine tumors not associated with multiple endocrine neoplasia type 1 syndrome. Lab Invest 79:671–677PubMedGoogle Scholar
  10. 10.
    Agarwal SK, Kennedy PA, Scacheri PC et al (2005) Menin molecular interactions: insights into normal functions and tumorigenesis. Horm Metab Res 37:369–374PubMedCrossRefGoogle Scholar
  11. 11.
    Higham AD, Bishop LA, Dimaline R et al (1999) Mutations of RegIalpha are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. Gastroenterology 116:1310–1318PubMedCrossRefGoogle Scholar
  12. 12.
    Solcia E, Fiocca R, Villani L et al (1995) Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Am J Surg Pathol 19(Suppl 1):S1–S7PubMedGoogle Scholar
  13. 13.
    Safatle-Ribeiro AV, Ribeiro U Jr, Corbett CE et al (2007) Prognostic value of immunohistochemistry in gastric neuroendocrine (carcinoid) tumors. Eur J Gastroenterol Hepatol 19(1):21–28PubMedCrossRefGoogle Scholar
  14. 14.
    Kagawa J, Honda S, Kodama M et al (2002) Enterochromaffin-like cell tumor induced by Helicobacter pylori infection in Mongolian gerbils. Helicobacter 7:390–397PubMedCrossRefGoogle Scholar
  15. 15.
    Tang LH, Luque EA, Efstathiou JA et al (1997) Gastrin receptor expression and function during rapid transformation of the enterochromaffin-like cells in an African rodent. Regul Pept 72:9–18PubMedCrossRefGoogle Scholar
  16. 16.
    Sjoblom S (1988) Clinical presentation and prognosis of gastrointestinal carcinoid tumors. Scand J Gastroenterol 23:779–787PubMedCrossRefGoogle Scholar
  17. 17.
    Rappel S, Altendorfhofmann A, Stolte M (1995) Prognosis of gastric carcinoid tumors. Digestion 56:455–462PubMedCrossRefGoogle Scholar
  18. 18.
    Solcia E, Klöppel G, Sobin LH et al (1999) Histological typing of endocrine tumours. Springer, BerlinGoogle Scholar
  19. 19.
    Bordi C, Yu JY, Baggi MT et al (1991) Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer 67:663–672PubMedCrossRefGoogle Scholar
  20. 20.
    Oberg K (1996) Neuroendocrine gastrointestinal tumours. Ann Oncol 7(5):453–463PubMedGoogle Scholar
  21. 21.
    Granberg D, Wilander E, Stridsberg M et al (1998) Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut 43(2):223–228PubMedCrossRefGoogle Scholar
  22. 22.
    Nobels FR, Kwekkeboom DJ, Coopmans W et al (1997) Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 82(8):2622–2628PubMedCrossRefGoogle Scholar
  23. 23.
    Campana D, Nori F, Pezzilli R et al (2008) Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 15(1):337–342PubMedCrossRefGoogle Scholar
  24. 24.
    Fykse V, Sandvik AK, Qvigstad G et al (2004) Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 39(7):621–628PubMedCrossRefGoogle Scholar
  25. 25.
    Shi W, Johnston CF, Buchanan KD et al (1998) Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. QJM 91(4):295–301PubMedCrossRefGoogle Scholar
  26. 26.
    Rehm H, Wiedenmann B, Betz H (1986) Molecular characterization of synaptophysin, a major calcium-binding protein of the synaptic vesicle membrane. EMBO J 5:535–541PubMedGoogle Scholar
  27. 27.
    Erickson JD, Schafer MK, Bonner TI et al (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93:5166–5171PubMedCrossRefGoogle Scholar
  28. 28.
    Rindi G, Paolotti D, Fiocca R et al (2000) Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. Virchows Arch 436:217–223PubMedCrossRefGoogle Scholar
  29. 29.
    Krenning EP, Kwekkeboom DJ, Oei HY et al (1994) Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann N Y Acad Sci 733:416–424PubMedCrossRefGoogle Scholar
  30. 30.
    Warner RR, O’Dorisio TM (2002) Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin Nucl Med 32(2):79–83PubMedCrossRefGoogle Scholar
  31. 31.
    Gilbrit F, Reynolds JC, Lubensky SA et al (2000) Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids; a prospective study. J Nucl Med 41:1646–1656Google Scholar
  32. 32.
    Eckardt AJ, Wassef W (2005) Diagnosis of subepithelial tumors in the GI tract. Endoscopy, EUS, and histology: bronze, silver, and gold standard? Gastrointest Endosc 62(2):209–212PubMedCrossRefGoogle Scholar
  33. 33.
    Ichikawa J, Tanabe S, Koizumi W et al (2003) Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy 35(3):203–206PubMedCrossRefGoogle Scholar
  34. 34.
    Chak A (2002) EUS in submucosal tumors. Gastrointest Endosc 56(4 Suppl):S43–S48PubMedCrossRefGoogle Scholar
  35. 35.
    Ahlman H, Kolby L, Lundell L et al (1994) Clinical management of gastric carcinoid tumors. Digestion 55(suppl 3):77–85PubMedCrossRefGoogle Scholar
  36. 36.
    Higham AD, Dimaline R, Varro A et al (1999) Octreotide suppression test predicts beneficial outcome from antrectomy in patients with gastric carcinoid tumor. Gastroenterology 114:817–822CrossRefGoogle Scholar
  37. 37.
    Harvey RF (1988) Spontaneous resolution of multifocal gastric enterochromaffin-like cell carcinoid tumours. Lancet 1(8589):821PubMedCrossRefGoogle Scholar
  38. 38.
    Brundler R, Gebbers JO, Criblez D (1999) Multiple gastric carcinoid tumors in chronic atrophic gastritis: long-term follow-up under conservative management. Schweiz Med Wochenschr 129:957–960PubMedGoogle Scholar
  39. 39.
    Ravizza D, Fiori G, Trovato C et al (2007) Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig Liver Dis 39(6):537–543PubMedCrossRefGoogle Scholar
  40. 40.
    Gladdy R, Strong V, Coit C et al (2008) Defining surgical indications for type 1 gastric carcinoid. Ann Surg Oncol 15(suppl 2):50Google Scholar
  41. 41.
    Gilligan CJ, Lawton GP, Tang LH et al (1995) Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 90:338–352PubMedGoogle Scholar
  42. 42.
    Kadikoylu G, Yavasoglu I, Yukselen V et al (2006) Treatment of solitary gastric carcinoid tumor by endoscopic polypectomy in a patient with pernicious anemia. World J Gastroenterol 12(26):4267–4269PubMedGoogle Scholar
  43. 43.
    Schindl M, Kaserer K, Niederle B (2001) Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg 136:49–54PubMedCrossRefGoogle Scholar
  44. 44.
    Manfredi S, Pagenault M, de Lajarte-Thirouard AS et al (2007) Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. Eur J Gastroenterol Hepatol 19(11):1021–1025PubMedCrossRefGoogle Scholar
  45. 45.
    Guillem P (2005) Gastric carcinoid tumours. Is there a place for antrectomy? Ann Chir 130(5):323–326PubMedCrossRefGoogle Scholar
  46. 46.
    Yalow RS, Berson SA (1970) Radioimmunoassay of gastrin. Gastroenterology 58:1–14PubMedGoogle Scholar
  47. 47.
    Ferraro G, Annibale B, Marignani M et al (1996) Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J Clin Endocrinol Metab 81:677–683PubMedCrossRefGoogle Scholar
  48. 48.
    Fykse V, Sandvik AK, Waldum HL (2005) One-year follow-up study of patients with enterochromaffin-like cell carcinoids after treatment with octreotide long-acting release. Scand J Gastroenterol 40(11):1269–1274PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2011

Authors and Affiliations

  • Linda Zhang
    • 1
  • Junko Ozao
    • 1
  • Richard Warner
    • 2
  • Celia Divino
    • 1
  1. 1.Department of SurgeryMount Sinai School of MedicineNew YorkUSA
  2. 2.Division of Gastroenterology, Department of MedicineMount Sinai School of MedicineNew YorkUSA

Personalised recommendations